Pfizer's latest COVID booster targets Omicron JN.1. Learn who should get it and why it’s essential for protection.

Australia’s Therapeutic Goods Administration (TGA) has recently approved a new COVID booster. The shot was developed by ...

The UK has become the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine, paving the way for mass vaccination. Britain's medicines regulator, the MHRA, says the jab, which ...

The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...

You might remember that people who are immunocompromised and received Pfizer or Moderna were eligible to receive a booster with either vaccine back in August. We did that because we learned ...

Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

Australia's Therapeutic Goods Administration has approved a new COVID booster by Pfizer targeting the JN.1 sub-variant of Omicron. Despite evolving variants, boosters remain crucial, especially for ...